RIYADH: Medical device and vaccine manufacturing is set to receive a boost after Saudi Arabia held partnership talks with Pfizer and Agfa HealthCare to localize advanced pharmaceutical technologies.
Saudi Industry and Mineral Resources Minister Bandar Alkhorayef met senior executives from Pfizer during an official visit to Belgium to explore cooperation in pharmaceutical manufacturing and opportunities to localize vaccine and medicine production in the Kingdom, according to a government statement.
The initiative aligns with the objectives of the Kingdom’s national industrial strategy and Saudi Vision 2030.
“The meeting discussed aspects of joint cooperation, exchange of expertise, and the transfer of advanced technologies in the manufacturing of vaccines and biopharmaceuticals to the Kingdom, strengthening integration in pharmaceutical supply chains, in addition to developing joint investments in high-quality projects that support the Kingdom’s pharmaceutical security objectives,” the release stated.
As part of the visit, Alkhorayef toured Pfizer’s manufacturing facilities in Brussels, where he was briefed on the company’s operations and key investments in the pharmaceutical and vaccine sector.
Company officials outlined Pfizer’s global role in vaccine and biopharmaceutical production and expressed interest in transferring similar technologies to the proposed facility in Saudi Arabia.
In a separate meeting, the minister held talks with the chief executive of Agfa HealthCare to discuss cooperation in the manufacturing of medical devices and advanced industrial solutions.
He visited the company’s industrial facilities and reviewed its efforts in developing medical imaging solutions, digital health data management systems, and advanced radiology technologies, in addition to its capabilities in producing specialized chemicals and green hydrogen membranes.
The meetings and site visits were conducted as part of Alkhorayef’s official trip to Belgium, aimed at strengthening economic partnerships and attracting high-quality investments while facilitating the transfer of advanced technologies in pharmaceutical and medical industries.
The push reflects Saudi Arabia’s broader strategy to build domestic capacity in critical industries following supply disruptions seen during the COVID-19 pandemic, when many countries moved to reduce reliance on imported medicines and medical equipment.
The Kingdom has since identified pharmaceuticals and biotechnology as priority sectors under its National Industrial Strategy, with the goal of creating a regional production hub serving Middle East and African markets.











